<DOC>
	<DOCNO>NCT01783990</DOCNO>
	<brief_summary>The BABY HUG Treatment Study design see treatment drug hydroxyurea ( also call HU ) child sickle cell disease could prevent organ damage , especially spleen kidney . There also chance treatment could prevent painful crisis , lung disease , stroke , blood infection .</brief_summary>
	<brief_title>Pediatric Hydroxyurea Phase III Clinical Trial ( BABY HUG ) Follow-up Observational Study II Protocol</brief_title>
	<detailed_description>The current observational trial , Follow-Up Study II ( designate FUS II ) include enhanced neuropsychological , brain , cardiac , pulmonary evaluation well characterize cohort subject . Measures spleen renal function marker DNA damage continue collect . Assessment target organ sickle cell disease include pulmonary cardiac function perform addition evaluation developmental aspect SCD potential HU toxicity .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>All subject enrol BABY HUG FollowUp I Study participate least 24 month eligible FollowUp Study II Subjects receive Stem Cell Transplant eligible enrollment</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>